glp 1 epilepsy GLP-1 Drugs Tied to Lower Risk An analysis on the role

Data on whether tirzepatide lowers cardiovascular outcomes is not expected until 2025

Based Complement

4,6 Efficacy A1C-Lowering Effects: Compared with other oral antihyperglycemic agents, DPP-4 inhibitors are considered to have intermediate glycemic efficacy

And while the study focused on blood sugar control, experts say it may also help explain why some people don't see the same weight loss results on GLP-1s

Protocol 2: tirzepatide microdose for autoimmune inflammation Goal: Leverage dual GIP/GLP-1 receptor activation for broader anti-inflammatory coverage Starting dose: 0.5 mg tirzepatide subcutaneously, once weekly Week 1 to 6: Hold at 0.5 mg